SynthesisFrontiers in immunology2021
Immune Response to Hepatitis B Virus Vaccine Among People Living With HIV: A Meta-Analysis.
Synthesis in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Hepatitis B surface antigen seroprevalence in Morocco (2000-2024): a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Immunogenicity and safety of the booster COVID-19 vaccine among people with HIV: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.Journal of virology · 2025Trial
- Antibody persistence of standard versus double three-dose hepatitis B vaccine in liver transplant children: a randomized controlled trial.Scientific reports · 2024Trial
- Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.The Lancet. Infectious diseases · 2023Trial
- High Burden of Occult Hepatitis B Infection in HIV-Infected Patients in Southern Vietnam: Insights from Serological and Molecular Analysis.International journal of molecular sciences · 2026Article
- Review
- HBV Serological Profiles and Vaccination Status in People with HIV in the Transition to a Tenofovir-Sparing Era: Insights from a Large HIV Cohort.Infectious diseases and therapy · 2026Article
- Reduced HAV IgG Seropositivity Among Unvaccinated People Living with HIV: The Weak Shield.Tropical medicine and infectious disease · 2026Article
- Managing HBV/HIV coinfection: from diagnostics to long-acting antiretroviral therapy.Clinical and experimental hepatology · 2026Review
- Article
- Use of dual ART in individuals with different HBV serological patterns.Current opinion in HIV and AIDS · 2026Review
- Seroprotection after a Standard Three-Dose Hepatitis B Vaccination Series in Immune-Mediated Rheumatic Diseases: A Retrospective Observational Study.Infectious diseases & clinical microbiology · 2026Article
- SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIV.Antibodies (Basel, Switzerland) · 2026Article
- Hepatitis B virus vaccination in people with HIV: what's new?Current opinion in HIV and AIDS · 2026Review
- Vaccine-preventable viral hepatitis in men living with HIV/AIDS - immunity and associated factors.BMC infectious diseases · 2026Observational
- A real-world pattern on the long-term durability of the immune response to hepatitis B vaccination among people living with HIV in China: an 8.5-year retrospective study.Frontiers in public health · 2026Article
- Risk factors for adverse events following rabies vaccination: a multivariate analysis of real-world data.Frontiers in public health · 2026Article
- Hepatitis B Vaccination Rates and Risk Factors Affecting Vaccine Response in People Living with HIV in Turkey.Current HIV research · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is conflicting evidence about whether a double dose of the hepatitis B virus (HBV) vaccine induces better immunity than the standard-dose vaccine for people living with HIV (PLWH). This study provides a meta-analysis that summarizes the efficacy of HBV vaccine regimens among HIV-infected patients, clarifying the role of particular factors such as dose and frequency of vaccination in vaccine responsiveness and highlighting the need for evidence-based practice to assess HBV vaccination among PLWH. Methods: Randomized clinical trials (RCTs) and prospective studies reporting vaccination response rates among PLWH were found through a search of PubMed, Cochrane, and the Web of Science. The key outcome was vaccine response. A random-effects model was used to estimate the pooled response rate. Subgroup analysis was conducted to evaluate key factors and explore sources of heterogeneity. Possible biases were assessed using quality and publication bias assessment. Results: Eligible studies included controlled trials that examined the effects of 17 interventional studies with 1,821 participants. Among PLWH who received the HBV vaccine, the pooled response rate of HBV vaccination was 71.5% (95% CI 64.0%-77.9%, Conclusions: In this meta-analysis, the double dose of the HBV vaccine and multiple injections were associated with better immune responses than the standard HBV vaccine regimen in PLWH. Higher seroconversion rates were observed in PLWH with high CD4 Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.